March 19, 2021

Isofol receives recommendation from iDSMB to complete the AGENT study for market registration as planned with 440 patients

Link to the press release >>

November 2, 2020

Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

Link to the press release >>

See how arfolitixorin
works in cancer cells

See the animation >>

Previous

Next

Startpage 2

Press releases & Latest news

Isofol completes recruitment of Japanese patients in the global phase III AGENT study

Isofol completes recruitment of Japanese patients in the global phase III AGENT study

May 6, 2021 by

GOTHENBURG, Sweden, May 6, 2021 – In December 2020, Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market:…

Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 400 million and a potential over-allotment option of up to approximately SEK 100 million

Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 400 million and a potential over-allotment option of up to approximately SEK 100 million

April 28, 2021 by

GOTHENBURG, Sweden, April 28, 2021 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), hereby announces that…

Interviewed made by Redeye

Interviewed made by Redeye

April 1, 2021 by Admin Isofol

Redeye has interviewed Ulf Jungnelius, CEO of Isofol, regarding the announcement that the AGENT study will be completed with 440…

Upcoming Events

May 14, 2021 - May 14, 2021
Interim Report Q1
May 14, 2021 - May 14, 2021
Extraordinary General Meeting
May 14, 2021 - May 14, 2021
Annual Report 2020
June 23, 2021 - June 23, 2021
Annual General Meeting 2021

©2019 Isofol Medical AB (publ) Biotech Center, Arvid Wallgrens Backe 20, SE-413 46 Gothenburg, Sweden.

Isofol´s Glossary

Isofol's website uses cookies to improve and customize your visit. By continuing you accept this.Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.